

Deprescription of Aspirin for Primary Prevention is Uncommon at Discharge in Hospitalized Patients with Gastrointestinal Bleeding

Darrick K. Li¹, Ritu Agarwal², Michelle L. Hughes¹, Shawn Y. Ong², Kenneth W. Hung¹, Jamil Alexis⁴, John Damianos³, Shreyak Sharma³, Loren Laine^{1,5} ¹Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT USA; ³Department of Medicine, Yale School of Medicine, New Haven, CT USA; ³Department of Medicine, Yale School of Medicine, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT USA; ⁴Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, In Haven, CT USA; ⁴Section of Gastroenterology, Department of Medicine, Bridgeport Hospital, Bridgeport, CT USA; ⁵VA Connecticut Healthcare System, West Haven, CT, USA

Background

- 29 million individuals are estimated to be on aspirin for primary prevention (ppASA).
- Primary prevention aspirin is associated with a 56% increased risk of GI bleeding (GIB).
- Current guidelines recommend deprescription of ppASA in patients with a history of GIB.
- Deprescription patterns of ppASA in hospitalized patients with GIB remain unknown.

Methods

- Identified all hospitalized patients at Yale-New Haven Hospital from 01/2014 and 10/2021 who developed GIB and were on ppASA.
- Primary outcome: ppASA deprescription at discharge
- Secondary outcomes:
- Post-discharge major adverse cardiac events (MACE)
- Post-discharge GIB hospitalization

Results


- 320 patients included in the final analysis (Table 1) • 41 died during their hospitalization
- <u>25 (9%) had ppASA deprescribed at discharge</u>
- <u>12 (4%) mentioned indication for ASA at discharge</u>
- 19 patients were lost to follow-up after hospitalization

Conclusions and Clinical Implications


- Results highlight a large gap in implementation of deprescription in patients with GIB and support the safety of aspirin deprescription in the absence of preexisting cardiovascular disease
- Quality improvement initiatives are needed for discharge medication review to ensure appropriate deprescription in this population

Primary prevention aspirin was rarely deprescribed at discharge in hospitalized patients with GIB.

Aspirin deprescription was not associated with increased risk of MACE in follow-up.



Median (IQR) follow-up time: 1103 days (367-1670)





Demographics	
Age	72(61-81)
Sex, male	149 (46.6%)
Race/Ethnicity	
White/Caucasian	238 (74.4%)
Black/African American	54 (16.9%)
Asian or Pacific Islander	8 (2.5%)
Other	20 (6.2%)
Ethnicity	
Hispanic or Latino	18 (5.6%)
Daily aspirin dose (81 mg)	297 (92.8%)
Medical Con	norbidities
Hypertension	278 (86.9%)
Diabetes Mellitus	137 (42.8%)
Chronic Kidney Disease	83 (25.9%)
Peptic Ulcer Disease	44 (13.8%)
Cirrhosis	21 (6.6%)
COVID-19	25 (7.8%)
Medica	itions
NSAIDs	16 (5.0%)
SSRIs	45 (14.1%)
Antiplatelets	1 (0.3%)
Anticoagulants	14 (4.4%)
Hospitalization	Characteristics
Endoscopic evaluation	172 (53.8%)
ICU admission	95 (29.7%)
In-hospital mortality	41 (12.8%)
GIB-related mortality	9 (2.8%)
Hospital LOS, days	5 (3-9)

Table 1. Baseline and hospitalization characteristics of patients on ppASA presenting with GIB (n=320). Median and interquartile range used for continuous variables. N (%) used for categorical variables.